Enoxacin treatment of urinary tract infections in elderly patients.
Sixty-seven elderly patients (61 female, six male) with a mean age of 82 years (range 67-95) were orally treated for 4-14 days with enoxacin (200 or 400 mg bd) for urinary tract infections in a non-comparative open study. Fifty-three patients had features of pyelonephritis, and 17 had indwelling catheters. Clinical and bacteriological assessments were made on day 0, between days 2 and 4, at the end of therapy, 5-9 days post-treatment. Patients whose response continued to be satisfactory were re-examined 4-6 weeks after the last dose. In 20 patients enoxacin concentrations were measured in samples of urine and serum during the study. Enoxacin therapy eliminated the causative pathogens in 98.5% of the patients after 2-4 days treatment and in 100% at the end of therapy. Overall results at the end of treatment were good or excellent in 84% of patients. Sixty patients (90%) at 5-9 days follow-up had a satisfactory response (51 had complete eradication of pathogen and nine re-infection). At 4-6 weeks follow-up, 46 patients (69%) remained completely infection free. Side effects of therapy were, in general, mild or moderate although four patients, all of whom had a history of cerebrovascular disturbance, suffered convulsions during study.
Huttunen
M
M
Kuopio Town Institute of Health, National Public Health Institute, Finland.
Kunnas
K
K
Saloranta
P
P
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002408:Catheters, Indwelling; D003556:Cystitis / Q000188:drug therapy; D004341:Drug Evaluation; D015365:Enoxacin; D005260:Female; D006801:Humans; D008297:Male; D009287:Naphthyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D014546:Urinary Catheterization; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D009287:Naphthyridines; D015365:Enoxacin